In this study, we examined the point prevalence rate of atypical features in bipolar disorder, and estimated the potential impact of these features on treatment practices in China. Using the atypical features criteria of the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV), we documented the atypical symptoms in 3 906 consecutive participants with bipolar disorder enrolled at 26 psychiatric services across China. We further assessed the association between atypical features and the treatment approaches, including the prescription of antidepressants. The overall point prevalence rate of atypical features was 9.1% among patients with various bipolar disorder subtypes. When the definition was broadened to include atypical features B, the overall rate increased to 11.8%. Interestingly, among patients with the mixed state and remission subtypes, there was a significant difference in the rates of antidepressant medication usage between patients who met and those who did not meet the criteria for atypical features B. These fi ndings indicate a trend of using antidepressants for these two types of patients with atypical features. Further, for both mixed state and remission patients, treatment approaches were related to atypical features B. Our findings provide evidence to assist clinicians to readily recognize atypical features in bipolar subtypes and can propose treatments based on these diagnoses.
INTRODUCTION
Bipolar disorder (BP) is characterized by recurring periods of high or low mood, thinking and activity, associated with hypomanic, manic, depressed, and mixed states [1] , making it difficult to diagnose. This complexity and diversity of symptoms has led to a number of different prevalence estimates. When taking into account type I (BP-I), type II (BP-II), and sub-threshold types, prevalence estimates have ranged from 1.5% to 6% in the USA [2] [3] [4] [5] [6] . In China,
estimates are less specific, as up to 91.7% of patients with mood disorders never seek medical help [7] , but the latest investigations conducted in four provinces place the prevalence rate somewhat lower than that in the USA, with 0.1% for BP-I and 0.3% for BP-II [7] . This discrepancy is unsurprising -diagnosing BP is still challenging for clinicians worldwide.
A particularly confounding factor in the difficulty faced by clinicians when making a diagnosis of BP, is 
Clinical Assessment
All patients enrolled in this study were diagnosed with subtypes of BP according to the ICD-10 criteria. Based on the DSM-IV definitions, ATFs were defined as mood reactivity plus two or more items of ATF B symptoms, which include hyperphagia, hypersomnia or weight gain, interpersonal rejection sensitivity, and leaden paralysis [1] .
The researchers also examined the point prevalence by ATF B criteria, which refers to a patient having at least two of the four symptoms listed above [14] .
the largely unacknowledged atypical features (ATFs), such as mood reactivity, hyperphagia, hypersomnia or weight gain, interpersonal rejection sensitivity, and leaden paralysis [1] that can manifest alongside the better-known basic characteristics. While ATFs were introduced into the fourth edition of the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV) after several studies on atypical depression [8] [9] [10] and other studies that have found overlaps between depressed patients with ATFs and BP-II [11] [12] [13] [14] [15] , the atypical features of patients with BP have still not been well-studied. As a result, there is a lack of coherent fi ndings related to ATFs in BP [13, 16, 17] .
A further challenge faced by clinicians is how to best treat those patients they do diagnose with BP. Earlier studies reported that atypical depression symptoms may preferentially respond to antidepressants -for example monoamine oxidase inhibitors and tricyclic antidepressants [18] [19] [20] -and later a prominent meta-analysis indicated that antidepressants are effective in the shortterm treatment of bipolar depression [21] . However, another study, the Systematic Treatment Enhancement Program for Bipolar Disorder, noted that the effects of maintained treatment showed no discernible difference between BP patients using antidepressants and those not using antidepressants [22] . At present, few treatment guidelines for BP recommend antidepressants as an adjunctive therapy to mood stabilizers, and no treatment guidelines recommend antidepressants as a monotherapy [23] [24] [25] [26] .
Despite these guidelines, a previous study reported that it is not uncommon to prescribe antidepressants for BP patients in China on a prolonged basis [27] .
Given the relatively low diagnostic rates of BP and the reluctance of people in China to seek treatment for mood disorders as well as the lack of adherence to treatment guidelines, there is a pressing need to investigate the diagnosis and treatment of BP in China. The present report was designed to fill that gap by investigating the point prevalence of ATFs in BP and assessing their impact on treatment methods in China.
PARTICIPANTS AND METHODS

Study Design
To establish a database of BP clinical pathway in China, higher signifi cance (P <0.001; Table 1 ).
Distribution of Atypical Features in BP
We used multinomial logistic regression to explore the relationship between ATF B features and six subtypes of BP by comparing clinical variables among them. Using remission type as the internal reference index (P <0.05, see Table S1 for details), the results of these analyses showed that the ATF B features were signifi cantly correlated with the subtypes of BP. First, we noted that the different subtypes exhibited different point prevalence rates of ATFs.
The point prevalence rates of all atypical symptoms were relatively higher in patients exhibiting a mixed state (Table   2 ). Interestingly, rejection sensitivity was the most common symptom in all the BP subtypes (ranging from 42.5% in patients with recurrent mania to 64.3% in patients with mixed state). Second, based on the DSM-IV defi nition of ATFs, the overall rate of patients who met the criteria was 9.1%, with a specific breakdown as follows: 5.3% of manic patients without psychotic symptoms; 8.7% of those patients with psychotic symptoms; 7.4% of hypomanic patients; 11.3% of recurrent mania patients; 6.9% of remission patients; and most strikingly, 28.1% of mixed state patients. Finally, the overall rate of patients who met the ATF B symptom criteria was 11.8%. Specifically, this was less common in patients diagnosed with mania without psychotic symptoms (7.0%), but most common in mixed state patients (33.2%).
Association between Atypical Features B and Use of Antidepressants
The proportions of patients with and without ATF-B using antidepressant medication in each subgroup are shown in Table 3 . Our analysis showed no signifi cant differences between ATF B and non-ATF B patients in the hypomania, mania without psychotic symptoms, mania with psychotic symptoms, or recurrent mania subgroup in the use of antidepressants. In mixed state patients, those with ATF B symptoms were more likely to be using antidepressants (P <0.01) than those without ATF-B. A similar relationship was found in remission patients (P <0.001).
Impact of Atypical Features B Symptoms on Medication Approach
The current findings did not indicate any significant
Statistical Analysis
All socio-demographic and clinical features were gathered from surveys and observations and then summarized with descriptive statistics that allowed for further comparison between different BP subtypes using the χ 2 test. Statistical signifi cance was set at α = 0.05. To explore the relationship between ATFs and six subtypes of BP, multinomial logistic regression was used (see Table S1 for details). Because 
RESULTS
Demographic and Clinical Characteristics
Among the 3 906 patients with varying subtypes of BP, analysis showed no significant differences in terms of gender distribution, race, current comorbidity-mental disorders, or current comorbidity-physical disorders.
However, some clinical characteristics showed significant differences (P <0.01) among the six subtypes of BP, notably mental health history and the number of episodes in the past year. Other variables, such as current state of episode, mood state at fi rst episode, family history, age at entry, age difference among most of the studied subtypeshypomania, mania without psychotic symptoms, mania with psychotic symptoms, mixed state, and recurrent maniain terms of medication used for treatment between patients that met the ATF B criteria and those who did not. However, in the remission subtype, the differences in treatment presented a significant correlation with the ATF B factor (P <0.001) ( Table 4) .
DISCUSSION
In the current study, a range of atypical symptoms was observed among all the currently known subtypes of BP.
Using the DSM-IV criteria to define ATFs, the overall point prevalence was 9.1% across all patients. When the definition was broadened to include ATF B, the overall rate increased to 11.8%. We further examined the impact of ATF B symptoms on treatment practices for BP and its subtypes in China, and obtained two interesting fi ndings: (1) among the mixed state and the remission patients, there were significant differences in the use of antidepressants between those who met and those who did not meet the criteria of ATF B; and (2) among remission patients, the medication type was associated with the presence of ATF B.
In this study, the point prevalence rate of ATFs was lower than that in previous reports. To date, only three comparable studies on BP have been conducted, and they reported prevalence rates using ATF B of 30% [17] , 32.6% [13] , and 38.8% [11] , while we found the point prevalence rate to be 11.8%. However, when the investigation of bipolar depression used the DSM-IV criteria for ATFs, the prevalence rate increased to 44.2% [14] . To our knowledge, this is the first survey on atypical features in BP by a national database in China, so this may explain some of the discrepancies. Such differences may mainly result from the variations in the populations studied. For example, the three comparable studies enrolled all types of BP patients, but in this study, we, for the fi rst time, investigated the point prevalence rate of ATFs in only six types of patients. This was to take into account the fact that atypical symptoms make an important contribution to the recognition of BP:
e.g., the characteristic of bipolarity predicted a higher likelihood of the diagnosis of BP in patients with major depressive disorder [28] . This decision was carefully thought out during the design of the study, as bipolarity is similar to the ATFs described in our study, and some evidence suggests that atypical symptoms are valuable in distinguishing BP-II disorder from depression [29, 30] .
Among the atypical symptoms present in BP, the rate for those categorized as "rejection sensitivity" was the highest in our study. This finding is concordant with the basic clinical characteristics of BP, and underlies the relationship between rejection sensitivity and irritability and related symptoms [1, 28] . We also found that each of the atypical symptoms was most common among those patients exhibiting a mixed state; a not unexpected finding [31] , since mixed state patients usually exhibit atypical depression symptoms, and atypical symptoms are among the core features of atypical depression in DSM-IV [1, 28] . Furthermore, some atypical symptoms such as hypersomnia have been assumed to indicate a balance of specifi city and sensitivity for the diagnosis of BP-II disorder among depressed patients [30] . By extension, this suggests that we should focus on the ATFs during the diagnosis of 
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mixed states, as a failure to recognize BP in those treated for major depressive disorder is common in China [32] .
In this study, we were also concerned about the impact of atypical symptoms on treatment approaches, such as the use of antidepressants. Several studies have highlighted the seriousness of the high prescription rate of antidepressants to treat bipolar disorder worldwide [33] [34] [35] , and the mainland of China is no exception. In China,
antidepressants are prescribed in many cases, even though their long-term use can have markedly negative outcomes, e.g., the risk of manic switch or suicide [34, 36] .
If patients with BP have some non-specific symptoms, and tricyclic antidepressants [18, 19] , but more recent studies have suggested that there is a low rate of manic switch for serotonin reuptake inhibitors, and norepinephrine and dopamine reuptake inhibitors (bupropion). Both the previous and current clinical experience may contribute to the prescription of antidepressants, even if there is no consensus on their effects on BP during the acute [37] or maintenance periods [22] . Despite these limitations, this study gives some guidance in refi ning further studies that can more effectively verify and expand the present results.
In conclusion, the current findings indicated that various atypical symptoms are commonly observed in all subtypes of BP (overall rate of 9.1% using the DSM-IV criteria for ATFs, 11.8% by the defi nition of ATF B). Of note, the ATFs were most common in mixed state patients.
Likewise, among mixed state and remission patients, there was a higher frequency of antidepressant use when the patients met the criteria of ATF B; specifi cally, for remission patients, the treatment approaches were usually affected by whether or not ATF B symptoms were present. While this study reports on a survey built around information from a national database, it provides a framework of conclusions that are suggestive of larger issues with treating BP in the mainland of China. In particular, the fi ndings highlight the need to strengthen the education of physicians on ATFs in BP, to help clinicians recognize different aspects of BP and depressive symptoms, and accordingly provide appropriate treatments.
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